{"transactions":[{"id":4624954,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-22T22:43:22.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":false,"shares":1635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":58066,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1635},"source":{"system":"sec-edgar","filing":"0001193125-26-398204","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526398204/ownership.xml","form_type":"4"}},{"id":4624953,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-22T22:43:22.000Z","date":"2026-09-16","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":13.65,"value":22317.75,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."}],"balance_after":8617,"source":{"system":"sec-edgar","filing":"0001193125-26-398204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526398204/ownership.xml","form_type":"4"}},{"id":4624952,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-22T22:43:22.000Z","date":"2026-09-16","kind":"exercise","planned":true,"acquired":true,"shares":1635,"price":4.14,"value":6768.9,"ownership":{"direct":true},"balance_after":10252,"source":{"system":"sec-edgar","filing":"0001193125-26-398204","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526398204/ownership.xml","form_type":"4"}},{"id":3522,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-09-03T22:55:11.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":false,"shares":584,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":2959,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":584},"source":{"system":"sec-edgar","filing":"0001193125-26-382245","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526382245/ownership.xml","form_type":"4"}},{"id":3521,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-03T22:55:11.000Z","date":"2026-09-01","kind":"sale","planned":true,"acquired":false,"shares":584,"price":14,"value":8176.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."}],"balance_after":8617,"source":{"system":"sec-edgar","filing":"0001193125-26-382245","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526382245/ownership.xml","form_type":"4"}},{"id":3520,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-09-03T22:55:11.000Z","date":"2026-09-01","kind":"exercise","planned":true,"acquired":true,"shares":584,"price":6.49,"value":3790.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."}],"balance_after":9201,"source":{"system":"sec-edgar","filing":"0001193125-26-382245","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526382245/ownership.xml","form_type":"4"}},{"id":685696,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T21:34:05.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":false,"shares":1635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":59701,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1635},"source":{"system":"sec-edgar","filing":"0001193125-26-354313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526354313/ownership.xml","form_type":"4"}},{"id":685695,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-08-17T21:34:05.000Z","date":"2026-08-13","kind":"exercise","planned":true,"acquired":false,"shares":1635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":61336,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1635},"source":{"system":"sec-edgar","filing":"0001193125-26-354313","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526354313/ownership.xml","form_type":"4"}},{"id":685694,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:34:05.000Z","date":"2026-08-17","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":12.2,"value":19947.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."}],"balance_after":8617,"source":{"system":"sec-edgar","filing":"0001193125-26-354313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526354313/ownership.xml","form_type":"4"}},{"id":685693,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:34:05.000Z","date":"2026-08-17","kind":"exercise","planned":true,"acquired":true,"shares":1635,"price":4.14,"value":6768.9,"ownership":{"direct":true},"balance_after":10252,"source":{"system":"sec-edgar","filing":"0001193125-26-354313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526354313/ownership.xml","form_type":"4"}},{"id":685692,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:34:05.000Z","date":"2026-08-13","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":12,"value":19620.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."}],"balance_after":8617,"source":{"system":"sec-edgar","filing":"0001193125-26-354313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526354313/ownership.xml","form_type":"4"}},{"id":685691,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-08-17T21:34:05.000Z","date":"2026-08-13","kind":"exercise","planned":true,"acquired":true,"shares":1635,"price":4.14,"value":6768.9,"ownership":{"direct":true},"balance_after":10252,"source":{"system":"sec-edgar","filing":"0001193125-26-354313","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526354313/ownership.xml","form_type":"4"}},{"id":718483,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:07:28.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":5752,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":3543,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":5752},"source":{"system":"sec-edgar","filing":"0001920738-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000004/ownership.xml","form_type":"4"}},{"id":718482,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-07-02T20:07:28.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":false,"shares":814,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":62971,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":814},"source":{"system":"sec-edgar","filing":"0001920738-26-000004","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000004/ownership.xml","form_type":"4"}},{"id":718481,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:07:28.000Z","date":"2026-06-30","kind":"sale","planned":true,"acquired":false,"shares":6566,"price":14,"value":91924.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on January 13, 2026."}],"balance_after":8617,"source":{"system":"sec-edgar","filing":"0001920738-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000004/ownership.xml","form_type":"4"}},{"id":718480,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:07:28.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":5752,"price":6.49,"value":37330.48,"ownership":{"direct":true},"balance_after":15183,"source":{"system":"sec-edgar","filing":"0001920738-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000004/ownership.xml","form_type":"4"}},{"id":718479,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-07-02T20:07:28.000Z","date":"2026-06-30","kind":"exercise","planned":true,"acquired":true,"shares":814,"price":4.14,"value":3369.96,"ownership":{"direct":true},"balance_after":9431,"source":{"system":"sec-edgar","filing":"0001920738-26-000004","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000004/ownership.xml","form_type":"4"}},{"id":726658,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-06-25T20:38:46.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":false,"shares":9810,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":63785,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":9810},"source":{"system":"sec-edgar","filing":"0001920738-26-000002","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000002/ownership.xml","form_type":"4"}},{"id":726657,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:38:46.000Z","date":"2026-06-23","kind":"sale","planned":true,"acquired":false,"shares":9810,"price":12,"value":117720.0,"ownership":{"direct":true},"balance_after":8617,"source":{"system":"sec-edgar","filing":"0001920738-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000002/ownership.xml","form_type":"4"}},{"id":726656,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2026-06-25T20:38:46.000Z","date":"2026-06-23","kind":"exercise","planned":true,"acquired":true,"shares":9810,"price":4.14,"value":40613.4,"ownership":{"direct":true},"footnotes":[{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F1","text":"Reflects 5,023 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":18427,"source":{"system":"sec-edgar","filing":"0001920738-26-000002","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000192073826000002/ownership.xml","form_type":"4"}},{"id":826507,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2026-03-27T20:30:03.000Z","date":"2026-03-25","kind":"grant","planned":false,"acquired":true,"shares":217000,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 25, 2026 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":217000,"derivative":{"exercise_price":9.88,"expiration_date":"2036-03-24","underlying":"Common Stock","underlying_shares":217000},"source":{"system":"sec-edgar","filing":"0001193125-26-129155","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312526129155/ownership.xml","form_type":"4"}},{"id":962165,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-12-19T21:10:38.000Z","date":"2025-12-16","kind":"exercise","planned":true,"acquired":false,"shares":1635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":73595,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1635},"source":{"system":"sec-edgar","filing":"0001193125-25-326851","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525326851/ownership.xml","form_type":"4"}},{"id":962164,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:10:38.000Z","date":"2025-12-16","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":10.9,"value":17821.5,"ownership":{"direct":true},"balance_after":3594,"source":{"system":"sec-edgar","filing":"0001193125-25-326851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525326851/ownership.xml","form_type":"4"}},{"id":962163,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-12-19T21:10:38.000Z","date":"2025-12-16","kind":"exercise","planned":true,"acquired":true,"shares":1635,"price":4.14,"value":6768.9,"ownership":{"direct":true},"balance_after":5229,"source":{"system":"sec-edgar","filing":"0001193125-25-326851","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525326851/ownership.xml","form_type":"4"}},{"id":994120,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-11-20T02:53:40.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":false,"shares":1635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":75230,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1635},"source":{"system":"sec-edgar","filing":"0001193125-25-288632","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525288632/ownership.xml","form_type":"4"}},{"id":994119,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-11-20T02:53:40.000Z","date":"2025-11-17","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":10.59,"value":17314.65,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."}],"balance_after":3594,"source":{"system":"sec-edgar","filing":"0001193125-25-288632","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525288632/ownership.xml","form_type":"4"}},{"id":994118,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-11-20T02:53:40.000Z","date":"2025-11-17","kind":"exercise","planned":true,"acquired":true,"shares":1635,"price":4.14,"value":6768.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."}],"balance_after":5229,"source":{"system":"sec-edgar","filing":"0001193125-25-288632","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525288632/ownership.xml","form_type":"4"}},{"id":1013292,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-27T22:19:56.000Z","date":"2025-10-24","kind":"exercise","planned":true,"acquired":false,"shares":1084,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":9295,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":1084},"source":{"system":"sec-edgar","filing":"0001193125-25-251874","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525251874/ownership.xml","form_type":"4"}},{"id":1013291,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-27T22:19:56.000Z","date":"2025-10-24","kind":"sale","planned":true,"acquired":false,"shares":2678,"price":12,"value":32136.0,"ownership":{"direct":true},"balance_after":3594,"source":{"system":"sec-edgar","filing":"0001193125-25-251874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525251874/ownership.xml","form_type":"4"}},{"id":1013290,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-27T22:19:56.000Z","date":"2025-10-24","kind":"exercise","planned":true,"acquired":true,"shares":1084,"price":6.49,"value":7035.16,"ownership":{"direct":true},"balance_after":6272,"source":{"system":"sec-edgar","filing":"0001193125-25-251874","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525251874/ownership.xml","form_type":"4"}},{"id":1015887,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-10-20T23:51:45.000Z","date":"2025-10-16","kind":"exercise","planned":true,"acquired":false,"shares":1635,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":76865,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":1635},"source":{"system":"sec-edgar","filing":"0001193125-25-243946","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525243946/ownership.xml","form_type":"4"}},{"id":1015886,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-20T23:51:45.000Z","date":"2025-10-16","kind":"sale","planned":true,"acquired":false,"shares":1635,"price":10.17,"value":16627.95,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."}],"balance_after":5188,"source":{"system":"sec-edgar","filing":"0001193125-25-243946","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525243946/ownership.xml","form_type":"4"}},{"id":1015885,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-20T23:51:45.000Z","date":"2025-10-16","kind":"exercise","planned":true,"acquired":true,"shares":1635,"price":4.14,"value":6768.9,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."}],"balance_after":6823,"source":{"system":"sec-edgar","filing":"0001193125-25-243946","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525243946/ownership.xml","form_type":"4"}},{"id":1019400,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-10-14T20:04:10.000Z","date":"2025-10-09","kind":"sale","planned":true,"acquired":false,"shares":2408,"price":10,"value":24080.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."}],"balance_after":5188,"source":{"system":"sec-edgar","filing":"0001193125-25-238995","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525238995/ownership.xml","form_type":"4"}},{"id":1031817,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2025-09-27T01:50:32.000Z","date":"2025-09-23","kind":"sale","planned":true,"acquired":false,"shares":2407,"price":8,"value":19256.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on June 6, 2025."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 3,222 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":7596,"source":{"system":"sec-edgar","filing":"0001193125-25-221028","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000119312525221028/ownership.xml","form_type":"4"}},{"id":1215369,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2025-03-11T00:00:20.000Z","date":"2025-03-06","kind":"grant","planned":false,"acquired":true,"shares":78500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"derivative.exercise_date","element":"exerciseDate","label":"F1","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 6, 2025 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":78500,"derivative":{"exercise_price":4.14,"expiration_date":"2035-03-05","underlying":"Common Stock","underlying_shares":78500},"source":{"system":"sec-edgar","filing":"0000950170-25-036696","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017025036696/ownership.xml","form_type":"4"}},{"id":1403821,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-09-18T21:46:02.000Z","date":"2024-09-16","kind":"exercise","planned":true,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":10379,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0000950170-24-107903","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024107903/ownership.xml","form_type":"4"}},{"id":1403820,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-09-18T21:46:02.000Z","date":"2024-09-16","kind":"sale","planned":true,"acquired":false,"shares":500,"price":16.33,"value":8165.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":6781,"source":{"system":"sec-edgar","filing":"0000950170-24-107903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024107903/ownership.xml","form_type":"4"}},{"id":1403819,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-09-18T21:46:02.000Z","date":"2024-09-16","kind":"exercise","planned":true,"acquired":true,"shares":500,"price":6.49,"value":3245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":7281,"source":{"system":"sec-edgar","filing":"0000950170-24-107903","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024107903/ownership.xml","form_type":"4"}},{"id":1426662,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-08-21T20:28:11.000Z","date":"2024-08-19","kind":"exercise","planned":true,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":10879,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0000950170-24-099505","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024099505/ownership.xml","form_type":"4"}},{"id":1426661,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-08-21T20:28:11.000Z","date":"2024-08-19","kind":"sale","planned":true,"acquired":false,"shares":500,"price":15,"value":7500.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":6781,"source":{"system":"sec-edgar","filing":"0000950170-24-099505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024099505/ownership.xml","form_type":"4"}},{"id":1426660,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-08-21T20:28:11.000Z","date":"2024-08-19","kind":"exercise","planned":true,"acquired":true,"shares":500,"price":6.49,"value":3245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":7281,"source":{"system":"sec-edgar","filing":"0000950170-24-099505","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024099505/ownership.xml","form_type":"4"}},{"id":1451924,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-07-19T00:22:41.000Z","date":"2024-07-16","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":32502,"derivative":{"exercise_price":8.04,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000950170-24-084725","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024084725/ownership.xml","form_type":"4"}},{"id":1451923,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-07-19T00:22:41.000Z","date":"2024-07-16","kind":"exercise","planned":true,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":11379,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0000950170-24-084725","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024084725/ownership.xml","form_type":"4"}},{"id":1451922,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-07-19T00:22:41.000Z","date":"2024-07-16","kind":"sale","planned":true,"acquired":false,"shares":1750,"price":27.11,"value":47442.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":6781,"source":{"system":"sec-edgar","filing":"0000950170-24-084725","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024084725/ownership.xml","form_type":"4"}},{"id":1451921,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-07-19T00:22:41.000Z","date":"2024-07-16","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":8.04,"value":10050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":8531,"source":{"system":"sec-edgar","filing":"0000950170-24-084725","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024084725/ownership.xml","form_type":"4"}},{"id":1451920,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-07-19T00:22:41.000Z","date":"2024-07-16","kind":"exercise","planned":true,"acquired":true,"shares":500,"price":6.49,"value":3245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":7281,"source":{"system":"sec-edgar","filing":"0000950170-24-084725","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024084725/ownership.xml","form_type":"4"}},{"id":1454703,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-07-15T22:13:08.000Z","date":"2024-07-11","kind":"exercise","planned":true,"acquired":false,"shares":1996,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":23004,"derivative":{"exercise_price":15.78,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":1996},"source":{"system":"sec-edgar","filing":"0000950170-24-083712","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024083712/ownership.xml","form_type":"4"}},{"id":1454702,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-07-15T22:13:08.000Z","date":"2024-07-11","kind":"sale","planned":true,"acquired":false,"shares":1996,"price":25,"value":49900.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":6781,"source":{"system":"sec-edgar","filing":"0000950170-24-083712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024083712/ownership.xml","form_type":"4"}},{"id":1454701,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-07-15T22:13:08.000Z","date":"2024-07-11","kind":"exercise","planned":true,"acquired":true,"shares":1996,"price":15.78,"value":31496.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"balance_after","element":"sharesOwnedFollowingTransaction","label":"F2","text":"Reflects 5,044 shares of the Issuer's common stock purchased under the Issuer's Employee Stock Purchase Plan in a transaction exempt under Rule 16b-3."}],"balance_after":8777,"source":{"system":"sec-edgar","filing":"0000950170-24-083712","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024083712/ownership.xml","form_type":"4"}},{"id":1460464,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-07-03T21:11:41.000Z","date":"2024-07-01","kind":"exercise","planned":true,"acquired":false,"shares":2916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":33752,"derivative":{"exercise_price":8.04,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":2916},"source":{"system":"sec-edgar","filing":"0000950170-24-081626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024081626/ownership.xml","form_type":"4"}},{"id":1460463,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-07-03T21:11:41.000Z","date":"2024-07-01","kind":"exercise","planned":true,"acquired":false,"shares":1332,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":11879,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":1332},"source":{"system":"sec-edgar","filing":"0000950170-24-081626","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024081626/ownership.xml","form_type":"4"}},{"id":1460462,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-07-03T21:11:41.000Z","date":"2024-07-01","kind":"sale","planned":true,"acquired":false,"shares":4248,"price":21.3648,"value":90757.6704,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $21.01 to $21.74, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1737,"source":{"system":"sec-edgar","filing":"0000950170-24-081626","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024081626/ownership.xml","form_type":"4"}},{"id":1460461,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-07-03T21:11:41.000Z","date":"2024-07-01","kind":"exercise","planned":true,"acquired":true,"shares":2916,"price":8.04,"value":23444.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":5985,"source":{"system":"sec-edgar","filing":"0000950170-24-081626","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024081626/ownership.xml","form_type":"4"}},{"id":1460460,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-07-03T21:11:41.000Z","date":"2024-07-01","kind":"exercise","planned":true,"acquired":true,"shares":1332,"price":6.49,"value":8644.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":3069,"source":{"system":"sec-edgar","filing":"0000950170-24-081626","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024081626/ownership.xml","form_type":"4"}},{"id":1473463,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-06-20T20:59:10.000Z","date":"2024-06-17","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":36668,"derivative":{"exercise_price":8.04,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000950170-24-075692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024075692/ownership.xml","form_type":"4"}},{"id":1473462,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-06-20T20:59:10.000Z","date":"2024-06-17","kind":"exercise","planned":true,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":13211,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0000950170-24-075692","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024075692/ownership.xml","form_type":"4"}},{"id":1473461,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-06-20T20:59:10.000Z","date":"2024-06-17","kind":"sale","planned":true,"acquired":false,"shares":1750,"price":23.7106,"value":41493.55,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $23.45 to $24.44, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1737,"source":{"system":"sec-edgar","filing":"0000950170-24-075692","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024075692/ownership.xml","form_type":"4"}},{"id":1473460,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-06-20T20:59:10.000Z","date":"2024-06-17","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":8.04,"value":10050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":3487,"source":{"system":"sec-edgar","filing":"0000950170-24-075692","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024075692/ownership.xml","form_type":"4"}},{"id":1473459,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-06-20T20:59:10.000Z","date":"2024-06-17","kind":"exercise","planned":true,"acquired":true,"shares":500,"price":6.49,"value":3245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":2237,"source":{"system":"sec-edgar","filing":"0000950170-24-075692","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024075692/ownership.xml","form_type":"4"}},{"id":1509227,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-05-21T00:35:08.000Z","date":"2024-05-16","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":37918,"derivative":{"exercise_price":8.04,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000950170-24-062637","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024062637/ownership.xml","form_type":"4"}},{"id":1509226,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-05-21T00:35:08.000Z","date":"2024-05-16","kind":"exercise","planned":true,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":13711,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0000950170-24-062637","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024062637/ownership.xml","form_type":"4"}},{"id":1509225,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-05-21T00:35:08.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":467,"price":25.7543,"value":12027.2581,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F3","text":"The transaction was executed in multiple trades in prices ranging from $25.67 to $25.92, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1737,"source":{"system":"sec-edgar","filing":"0000950170-24-062637","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024062637/ownership.xml","form_type":"4"}},{"id":1509224,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-05-21T00:35:08.000Z","date":"2024-05-16","kind":"sale","planned":true,"acquired":false,"shares":1283,"price":25.342,"value":32513.786,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $24.67 to $25.65, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote.."}],"balance_after":2204,"source":{"system":"sec-edgar","filing":"0000950170-24-062637","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024062637/ownership.xml","form_type":"4"}},{"id":1509223,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-05-21T00:35:08.000Z","date":"2024-05-16","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":8.04,"value":10050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":3487,"source":{"system":"sec-edgar","filing":"0000950170-24-062637","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024062637/ownership.xml","form_type":"4"}},{"id":1509222,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-05-21T00:35:08.000Z","date":"2024-05-16","kind":"exercise","planned":true,"acquired":true,"shares":500,"price":6.49,"value":3245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":2237,"source":{"system":"sec-edgar","filing":"0000950170-24-062637","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024062637/ownership.xml","form_type":"4"}},{"id":1539315,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-04-19T00:48:28.000Z","date":"2024-04-16","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":39168,"derivative":{"exercise_price":8.04,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000950170-24-045702","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024045702/ownership.xml","form_type":"4"}},{"id":1539314,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-04-19T00:48:28.000Z","date":"2024-04-16","kind":"exercise","planned":true,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":14211,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0000950170-24-045702","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024045702/ownership.xml","form_type":"4"}},{"id":1539313,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-04-19T00:48:28.000Z","date":"2024-04-16","kind":"sale","planned":true,"acquired":false,"shares":1750,"price":25.74,"value":45045.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":1737,"source":{"system":"sec-edgar","filing":"0000950170-24-045702","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024045702/ownership.xml","form_type":"4"}},{"id":1539312,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-04-19T00:48:28.000Z","date":"2024-04-16","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":8.04,"value":10050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":3487,"source":{"system":"sec-edgar","filing":"0000950170-24-045702","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024045702/ownership.xml","form_type":"4"}},{"id":1539311,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-04-19T00:48:28.000Z","date":"2024-04-16","kind":"exercise","planned":true,"acquired":true,"shares":500,"price":6.49,"value":3245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":2237,"source":{"system":"sec-edgar","filing":"0000950170-24-045702","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024045702/ownership.xml","form_type":"4"}},{"id":1550382,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-04-03T23:18:33.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":1909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F5","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":46182,"derivative":{"exercise_price":20.24,"expiration_date":"2033-02-09","underlying":"Common Stock","underlying_shares":1909},"source":{"system":"sec-edgar","filing":"0000950170-24-041418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024041418/ownership.xml","form_type":"4"}},{"id":1550381,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-04-03T23:18:33.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":1996,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":21008,"derivative":{"exercise_price":15.78,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":1996},"source":{"system":"sec-edgar","filing":"0000950170-24-041418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024041418/ownership.xml","form_type":"4"}},{"id":1550380,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-04-03T23:18:33.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":2916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":40418,"derivative":{"exercise_price":8.04,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":2916},"source":{"system":"sec-edgar","filing":"0000950170-24-041418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":7,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024041418/ownership.xml","form_type":"4"}},{"id":1550379,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-04-03T23:18:33.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":false,"shares":1332,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":14711,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":1332},"source":{"system":"sec-edgar","filing":"0000950170-24-041418","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":6,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024041418/ownership.xml","form_type":"4"}},{"id":1550378,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-04-03T23:18:33.000Z","date":"2024-04-01","kind":"sale","planned":true,"acquired":false,"shares":8153,"price":31.78,"value":259102.34,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":1737,"source":{"system":"sec-edgar","filing":"0000950170-24-041418","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024041418/ownership.xml","form_type":"4"}},{"id":1550377,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-04-03T23:18:33.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":1909,"price":20.24,"value":38638.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":9890,"source":{"system":"sec-edgar","filing":"0000950170-24-041418","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024041418/ownership.xml","form_type":"4"}},{"id":1550376,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-04-03T23:18:33.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":1996,"price":15.78,"value":31496.88,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":7981,"source":{"system":"sec-edgar","filing":"0000950170-24-041418","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024041418/ownership.xml","form_type":"4"}},{"id":1550375,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-04-03T23:18:33.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":2916,"price":8.04,"value":23444.64,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":5985,"source":{"system":"sec-edgar","filing":"0000950170-24-041418","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024041418/ownership.xml","form_type":"4"}},{"id":1550374,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-04-03T23:18:33.000Z","date":"2024-04-01","kind":"exercise","planned":true,"acquired":true,"shares":1332,"price":6.49,"value":8644.68,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":3069,"source":{"system":"sec-edgar","filing":"0000950170-24-041418","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024041418/ownership.xml","form_type":"4"}},{"id":1557680,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-03-29T20:52:39.000Z","date":"2024-03-27","kind":"exercise","planned":true,"acquired":false,"shares":1491,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on the first anniversary measured from October 1, 2021 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":54167,"derivative":{"exercise_price":25.98,"expiration_date":"2031-09-30","underlying":"Common Stock","underlying_shares":1491},"source":{"system":"sec-edgar","filing":"0000950170-24-038731","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024038731/ownership.xml","form_type":"4"}},{"id":1557679,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-03-29T20:52:39.000Z","date":"2024-03-27","kind":"exercise","planned":true,"acquired":false,"shares":4342,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"25% of the shares subject to the option vest on the first anniversary measured from October 1, 2021 (the \"Vesting Commencement Date\"), and 1/48th of the total number of shares vest in thirty-six (36) successive and equal monthly installments thereafter, such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":55658,"derivative":{"exercise_price":25.98,"expiration_date":"2031-09-30","underlying":"Common Stock","underlying_shares":4342},"source":{"system":"sec-edgar","filing":"0000950170-24-038731","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024038731/ownership.xml","form_type":"4"}},{"id":1557678,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-03-29T20:52:39.000Z","date":"2024-03-27","kind":"sale","planned":true,"acquired":false,"shares":5833,"price":35.0438,"value":204410.4854,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"price","element":"transactionPricePerShare","label":"F2","text":"The transaction was executed in multiple trades in prices ranging from $35.00 to $35.20, inclusive. The price reported in Column 4 above reflects the weighted average sale price. The reporting person hereby undertakes to provide to the Securities and Exchange Commission staff, the Issuer, or a security holder of the Issuer, upon request, full information regarding the number of shares sold at each respective price within the range set forth in this footnote."}],"balance_after":1737,"source":{"system":"sec-edgar","filing":"0000950170-24-038731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024038731/ownership.xml","form_type":"4"}},{"id":1557677,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-03-29T20:52:39.000Z","date":"2024-03-27","kind":"exercise","planned":true,"acquired":true,"shares":1491,"price":25.98,"value":38736.18,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":7570,"source":{"system":"sec-edgar","filing":"0000950170-24-038731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024038731/ownership.xml","form_type":"4"}},{"id":1557676,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-03-29T20:52:39.000Z","date":"2024-03-27","kind":"exercise","planned":true,"acquired":true,"shares":4342,"price":25.98,"value":112805.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":6079,"source":{"system":"sec-edgar","filing":"0000950170-24-038731","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024038731/ownership.xml","form_type":"4"}},{"id":1566238,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-03-20T20:40:59.000Z","date":"2024-03-18","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":43334,"derivative":{"exercise_price":8.04,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000950170-24-034227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024034227/ownership.xml","form_type":"4"}},{"id":1566237,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-03-20T20:40:59.000Z","date":"2024-03-18","kind":"exercise","planned":true,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":16043,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0000950170-24-034227","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024034227/ownership.xml","form_type":"4"}},{"id":1566236,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-03-20T20:40:59.000Z","date":"2024-03-18","kind":"sale","planned":true,"acquired":false,"shares":1750,"price":31.27,"value":54722.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":1737,"source":{"system":"sec-edgar","filing":"0000950170-24-034227","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024034227/ownership.xml","form_type":"4"}},{"id":1566235,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-03-20T20:40:59.000Z","date":"2024-03-18","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":8.04,"value":10050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":3487,"source":{"system":"sec-edgar","filing":"0000950170-24-034227","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024034227/ownership.xml","form_type":"4"}},{"id":1566234,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-03-20T20:40:59.000Z","date":"2024-03-18","kind":"exercise","planned":true,"acquired":true,"shares":500,"price":6.49,"value":3245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":2237,"source":{"system":"sec-edgar","filing":"0000950170-24-034227","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024034227/ownership.xml","form_type":"4"}},{"id":1610335,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-02-29T23:01:58.000Z","date":"2024-02-27","kind":"exercise","planned":true,"acquired":false,"shares":1909,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of February 10, 2023 (the \"Vesting Commencement Date\"), such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":48091,"derivative":{"exercise_price":20.24,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":1909},"source":{"system":"sec-edgar","filing":"0000950170-24-023330","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024023330/ownership.xml","form_type":"4"}},{"id":1610334,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-29T23:01:58.000Z","date":"2024-02-27","kind":"sale","planned":true,"acquired":false,"shares":1909,"price":30,"value":57270.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":1737,"source":{"system":"sec-edgar","filing":"0000950170-24-023330","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024023330/ownership.xml","form_type":"4"}},{"id":1610333,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-29T23:01:58.000Z","date":"2024-02-27","kind":"exercise","planned":true,"acquired":true,"shares":1909,"price":20.24,"value":38638.16,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":3646,"source":{"system":"sec-edgar","filing":"0000950170-24-023330","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024023330/ownership.xml","form_type":"4"}},{"id":1629759,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-02-21T22:41:01.000Z","date":"2024-02-16","kind":"exercise","planned":true,"acquired":false,"shares":1250,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":44584,"derivative":{"exercise_price":8.04,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":1250},"source":{"system":"sec-edgar","filing":"0000950170-24-018155","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":5,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024018155/ownership.xml","form_type":"4"}},{"id":1629758,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right To Buy)","published_at":"2024-02-21T22:41:01.000Z","date":"2024-02-16","kind":"exercise","planned":true,"acquired":false,"shares":500,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F2","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of June 16, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":16543,"derivative":{"exercise_price":6.49,"expiration_date":"2032-06-17","underlying":"Common Stock","underlying_shares":500},"source":{"system":"sec-edgar","filing":"0000950170-24-018155","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":4,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024018155/ownership.xml","form_type":"4"}},{"id":1629757,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-21T22:41:01.000Z","date":"2024-02-16","kind":"sale","planned":true,"acquired":false,"shares":1750,"price":27.67,"value":48422.5,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":1737,"source":{"system":"sec-edgar","filing":"0000950170-24-018155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":3,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024018155/ownership.xml","form_type":"4"}},{"id":1629756,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-21T22:41:01.000Z","date":"2024-02-16","kind":"exercise","planned":true,"acquired":true,"shares":1250,"price":8.04,"value":10050.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":3487,"source":{"system":"sec-edgar","filing":"0000950170-24-018155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":2,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024018155/ownership.xml","form_type":"4"}},{"id":1629755,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Common Stock","published_at":"2024-02-21T22:41:01.000Z","date":"2024-02-16","kind":"exercise","planned":true,"acquired":true,"shares":500,"price":6.49,"value":3245.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."}],"balance_after":2237,"source":{"system":"sec-edgar","filing":"0000950170-24-018155","document":"ownership.xml","document_sequence":1,"table":"nonDerivative","row_type":"transaction","position":1,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024018155/ownership.xml","form_type":"4"}},{"id":1649570,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-13T02:04:28.000Z","date":"2024-02-08","kind":"exercise","planned":true,"acquired":false,"shares":1996,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F4","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of March 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":23004,"derivative":{"exercise_price":15.78,"expiration_date":"2032-01-31","underlying":"Common Stock","underlying_shares":1996},"source":{"system":"sec-edgar","filing":"0000950170-24-014119","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":9,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024014119/ownership.xml","form_type":"4"}},{"id":1649569,"issuer":{"id":2419,"kind":"organization","name":"4D Molecular Therapeutics, Inc.","symbol":"FDMT"},"owners":[{"id":2420,"kind":"person","name":"Bizily Scott","position":1,"cik":"0001920738","reported_name":"Bizily Scott","relationship":{"director":false,"officer":true,"ten_percent_owner":false,"other":false,"officer_title":"Chief Legal Officer"}}],"security":"Stock Option (Right to Buy)","published_at":"2024-02-13T02:04:28.000Z","date":"2024-02-08","kind":"exercise","planned":true,"acquired":false,"shares":2916,"price":0,"value":0.0,"ownership":{"direct":true},"footnotes":[{"field":"kind","element":"transactionCoding","label":"F1","text":"Transaction made pursuant to a 10b5-1 trading plan adopted by the Reporting Person on October 10, 2023."},{"field":"derivative.exercise_date","element":"exerciseDate","label":"F3","text":"The shares underlying the stock option award shall vest and become exercisable as to 1/48th of the underlying shares on each monthly anniversary of September 1, 2022 (the \"Vesting Commencement Date\") such that 100% of the shares subject to the option will be fully vested and exercisable on the fourth anniversary of the Vesting Commencement Date, while the grantee remains a service provider to the Company."}],"balance_after":45834,"derivative":{"exercise_price":8.04,"expiration_date":"2032-08-31","underlying":"Common Stock","underlying_shares":2916},"source":{"system":"sec-edgar","filing":"0000950170-24-014119","document":"ownership.xml","document_sequence":1,"table":"derivative","row_type":"transaction","position":8,"url":"https://www.sec.gov/Archives/edgar/data/1920738/000095017024014119/ownership.xml","form_type":"4"}}],"next_cursor":"2024-02-13T02:04:28.000000Z,1649569"}